Showing 13,301 - 13,320 results of 105,122 for search '(( a step decrease ) OR ( 5 ((((we decrease) OR (mean decrease))) OR (a decrease)) ))', query time: 1.83s Refine Results
  1. 13301
  2. 13302
  3. 13303

    Data_Sheet_1_NBCe2 (Slc4a5) Is Expressed in the Renal Connecting Tubules and Cortical Collecting Ducts and Mediates Base Extrusion.PDF by Dagne Barbuskaite (740897)

    Published 2020
    “…In isolated renal CNT and CCD, genetic deletion of NBCe2 leads to decreased net base extrusion. To determine the role of renal NBCe2 in the development of hypertension, we generated CNT and intercalated cell NBCe2 knockout mice by crossing an Slc4a5 lox mouse with mice expressing cre recombinase under the V-ATPase B1 subunit promotor. …”
  4. 13304
  5. 13305
  6. 13306
  7. 13307
  8. 13308

    (a, b) The probability of failing to be matched conditioned on attractiveness <i>a</i> and degree <i>k</i> (<i>P</i><sub>not</sub>(<i>a</i>, <i>k</i>)) decreases exponentially with <i>a</i> and <i>k</i> in scale-free networks with <i>P</i>(<i>k</i>) ∼ <i>k</i><sup>−<i>γ</i></sup>, <i>γ</i> = 3 and ⟨<i>k</i>⟩ = 5. by Tao Jia (756099)

    Published 2015
    “…<p>(a, b) The probability of failing to be matched conditioned on attractiveness <i>a</i> and degree <i>k</i> (<i>P</i><sub>not</sub>(<i>a</i>, <i>k</i>)) decreases exponentially with <i>a</i> and <i>k</i> in scale-free networks with <i>P</i>(<i>k</i>) ∼ <i>k</i><sup>−<i>γ</i></sup>, <i>γ</i> = 3 and ⟨<i>k</i>⟩ = 5.…”
  9. 13309

    Inhibition of epithelial HH/GLI signaling leads to decreased cell proliferation in specific domains of the fungiform papilla. by Alexandre N. Ermilov (3365972)

    Published 2016
    “…<p><b>A,B</b>. p63-positive proliferating cells are continuous in basal epithelium of the FP (A, arrows) and in perigemmal cells around the taste bud (B,arrows). …”
  10. 13310
  11. 13311
  12. 13312

    Decreased proliferation in tuft endothelium despite increased VEGFA level in N-CAM deficient retinas in OIR. by Joakim Håkansson (200855)

    Published 2011
    “…Although not significant with a 5% level of significance, there is a tendency of increase in all isoforms with the highest relative elevation in VEGFA<sub>120</sub>. …”
  13. 13313
  14. 13314
  15. 13315
  16. 13316
  17. 13317

    The Numerical data used in all figures. by Fa Dai (15810913)

    Published 2023
    “…However, the mechanism on how AJ01 breaks the AjTmod-stabilized cytoskeleton for internalization remains unclear. Here, we identified a novel AJ01 Type III secretion system (T3SS) effector of leucine-rich repeat-containing serine/threonine-protein kinase (STPKLRR) with five LRR domains and a serine/threonine kinase (STYKc) domain, which could specifically interact with tropomodulin domain of AjTmod. …”
  18. 13318

    Primers. by Fa Dai (15810913)

    Published 2023
    “…However, the mechanism on how AJ01 breaks the AjTmod-stabilized cytoskeleton for internalization remains unclear. Here, we identified a novel AJ01 Type III secretion system (T3SS) effector of leucine-rich repeat-containing serine/threonine-protein kinase (STPKLRR) with five LRR domains and a serine/threonine kinase (STYKc) domain, which could specifically interact with tropomodulin domain of AjTmod. …”
  19. 13319

    A higher mean amplitude or lower standard deviation of the EOD of the swimming fish facilitates estimation of beat frequency at the receptor level. by Na Yu (151735)

    Published 2012
    “…<p>(A) The height (solid line) of the peak of at the beat frequency, , and the width (dashed line) of this peak at the coherence value of 0.15 increase and slightly decrease, respectively, with (with fixed  = 0.1). …”
  20. 13320

    Ganaxolone: A Review in Epileptic Seizures Associated with Cyclin‑Dependent Kinase‑Like 5 Deficiency Disorder by Sheridan M. Hoy (4897468)

    Published 2024
    “…While somnolence and sedation are related to the dose of ganaxolone, they appear early in treatment and may decrease with continued therapy. Thus, although current evidence is somewhat limited, adjunctive ganaxolone could be a valuable therapeutic option for patients aged 2–17 years with epileptic seizures associated with CDD.…”